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Introduction
p27kip1 is a member of the cdk inhibitory proteins, with an
important role coordinating the activation of cyclin E-cdk2 with
accumulation of cyclin D-cdk4 and initiating the timely exit of
cells from the cell cycle in response to antimitogenic signals.
Three features of p27 make it a strong candidate as a target to
consider in cancer therapy. First, while not mutated or lost at the
gene level, the abundance of the protein has proven to be a reli-
able prognostic marker for disease progression in a diverse
group of human neoplasms. This has been recapitulated in a
number of organ-specific mouse models. Second, many cancer
therapies are effective only in cells that are actively engaged in
the cell cycle. Given that p27 inhibits cell proliferation, its
expression may affect the efficacy of the therapies. Third, the
amount of p27 in a cell is largely controlled posttranscriptionally
by a number of pathways implicated in human cancer. These
features are interwoven such that modulating p27 levels can
have unforeseen consequences on therapy. In a clinical setting,
growth arrest is a double-edged sword that might inadvertently
lead to increased cell survival and resistance to cytotoxic
agents, while increasing proliferation may increase chemother-
apeutic efficiency.
p27 and cell cycle control
The “Rb pathway” is the major route by which mitogenic signals
promote proliferation (Sherr and McCormick, 2002). Disruption of
this pathway, by either overexpression of cyclin D, loss of the Ink4
inhibitor p16, mutation of cdk4 to a p16-resistant form, or even
loss or mutation of Rb itself, are commonly associated with
increased proliferation of cancer cells. An alternate route to con-
trol proliferation is through antimitogenic signals, which lead to
cell cycle exit. This route functions through the cdk inhibitors.
p27KIP1 (hereafter referred to as p27) is one member of the
Cip/Kip family of cdk inhibitors, whose principle role in cell cycle
exit is to inhibit the cyclin E-cdk2 kinase. In proliferating cells, p27
is primarily associated with cyclin D-cdk4/6 complexes, but these
complexes are catalytically active. The sequestration of p27 by
cyclin D-cdk4/6 complexes effectively frees cdk2 from inhibition
and allows both cdk4/6 and cdk2 to remain active.The movement
of p27 helps to establish a balance between proliferation (when
associated with cdk4) and arrest (when associated with cdk2).
The amount of p27 increases in quiescent cells or cells
undergoing differentiation, and it is a rate-determining compo-
nent of cell cycle exit in a number of cell types. Although it is
unclear how differentiation signals trigger accumulation of p27,
it is clear that mitogens and extracellular matrix adhesion sig-
nals can promote p27 degradation, allowing quiescent cells to
reenter the cell cycle. p27 knockout animals develop hyperpla-
sia in multiple organs, resulting in a mouse roughly 20%–30%
larger than their wild-type counterparts, consistent with a role
for p27 in both differentiation and proliferation (Fero et al., 1996;
Kiyokawa et al., 1996; Nakayama et al., 1996). Surprisingly, p27
null animals are relatively free of malignancy, with the exception
of pituitary hyperplasia that can develop into adenoma with age
and prostatic hyperplasia that becomes increasingly severe
with age (Cordon-Cardo et al., 1998). Thus, the absence of p27
alone indicates that it might be a weak tumor suppressor of a
narrowly defined group of cells, largely affecting the decision of
cells to exit the cell cycle. However, its absence alone cannot
provide the proliferation impetus required for most neoplasms.
p27 and cancer
p27 does not follow Knudson’s classic “two-hit hypothesis” of
tumor suppression; homozygous loss or silencing of the locus in
human tumors is extremely rare. However, an inverse correla-
tion between p27 protein levels and prognosis was first noted in
colon cancer and later in cancers of the breast, prostate, blad-
der, lung, glia, liver, larynx, ovary, stomach, and other tissues
(reviewed extensively in Lloyd et al., 1999; Philipp-Staheli et al.,
2001; Slingerland and Pagano, 2000; Tsihlias et al., 1999). The
loss of p27 function in human cancers and the prognostic signif-
icance associated with reduction in p27 suggested that it might
be a valuable target for both stratifying patient risk and, per-
haps, selecting treatment.
Nevertheless, before considering p27 in this way, one first
needed to ascertain whether loss of p27 was a causal or conse-
quential effect. This was addressed in a number of mouse mod-
els where the effect of p27 deficiency on tumor progression was
analyzed. In these models, p27 was shown to be a dosage-
dependent tumor suppressor. Carcinogen challenge demon-
strated that the loss of a single allele of p27 increased the
frequency and decreased the latency of tumors to a level inter-
mediate to that seen in wild-type and null counterparts (Fero et
al., 1998). Furthermore, the remaining allele was intact in these
tumors, leading many to call p27 a haploinsufficient tumor sup-
pressor. However, haploinsufficiency is when the phenotype of
the null is equivalent to the heterozygote and animals nullizy-
gous for p27 have an even further increased rate of tumor
formation in the presence of carcinogens. Consequently,
dosage-dependent is probably more appropriate. A similar
dosage effect may be at work in human tumors, where, in some
leukemias and lymphomas, hemizygous deletion of the p27
locus 12p13 has been detected without additional mutation of
the second allele (Philipp-Staheli et al., 2001).
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p27 deficiency also enhanced the rate of tumor formation in
the mouse in a number of tissues in cooperation with a number
of specific oncogenic stimuli (Figure 1). In the prostate, about
half of the Pten+/− mice develop prostatic intraepithelial neoplas-
tic (PIN) lesions, with none progressing to carcinoma-in-situ.
When Pten+/− mice are crossed into a p27−/− background, the
incidence of PIN lesions increases to 100% and many develop
to carcinoma-in-situ, with an occasional invasive tumor
observed (Di Cristofano et al., 2001). Thus, p27 loss not only
increased the number of animals afflicted, it also accelerated
the rate at which tumors progressed. p27 appears to be dosage-
dependent in this context: the frequency and latency of tumors
in the Pten+/−; p27+/− animals are intermediate to those seen in
the Pten+/− and the Pten+/−; p27−/− animals. The enhancing effect
of p27 deficiency is not restricted to a particular oncogenic
event or even a particular tissue. Similar observations have
been reported in the pituitary of both Rb+/−; p27−/− (Park et al.,
1999) and cdk4R24C/R24C; p27−/− mice (R24C is a knockin
allele of an Ink4 resistant cdk4 mutant) (Sotillo et al., 2001), in
the gonads using inhibin−/−; p27−/− (Cipriano et al., 2001), in the
colon using Min/−; p27−/− (Philipp-Staheli et al., 2002), and more
recently, in lymphocytes using Eµ-myc; p27−/− (Marins and
Berns, 2002). In the Eµ-myc model, loss of p27, but not loss of
p21, synergizes with myc expression (Marins and Berns, 2002),
highlighting an important distinction between these two
inhibitors. The fact that p27 loss in mice significantly affects
tumor progression, in conjunction with the observations that its
levels are reduced in human tumors, suggests that restoring
p27 might have a beneficial clinical effect. On the other hand,
inhibiting proliferation may contribute to treatment resistance to
current therapies, because many of these are dependent on
cells being engaged in the cell cycle. Thus, it is important to
determine how low p27 status contributes to the evolution of the
tumor and modulates the responses of that tumor type to preex-
isting chemotherapies.
It is well established that p27 is an important component of
the pathways by which cells respond to antimitogenic signals,
and these signals can interfere with tumor development in two
ways (Massagué et al., 2000; Sherr, 2000). First, because
antimitogens obviously inhibit cell proliferation, the loss of p27
might collaborate with an oncogenic event to increase the rate
of cell proliferation.There is ample evidence in lymphoma, blad-
der, prostate, and liver cancer (Slingerland and Pagano, 2000)
that p27 loss is correlated with an increase in proliferation index.
This is also exemplified in the Pten/p27 and Min/p27 mouse
models. In Pten+/−; p27−/− animals, the uninvolved prostate
glands show increased Ki67 staining without any change in the
rate of apoptosis (Di Cristofano et al., 2001).
However, low p27 expression does not correlate with prolif-
eration index in breast, colon, esophagus, thyroid, and astrocyt-
ic cancers (Lloyd et al., 1999; Tsihlias et al., 1999). This raised
the possibility of another distinct mechanism by which reducing
p27 levels could contribute to the neoplastic state. Oncogenic
events sensitize cells toward an apoptotic end when they are
confronted with antiproliferative signals that interfere with the
replication of their DNA (de Stanchina et al., 1998). Because
antimitogens can also prevent DNA replication, they can also
trigger apoptosis in oncogenically activated cells. Thus, the loss
of p27 may desensitize tumor cells to antimitogenic signals, pre-
venting apoptosis during their evolution. This principle is exem-
plified in the Rb/p27 model. In Rb+/−; p27−/− animals, p27
deficiency enhances the rate and aggressiveness of pituitary
tumors, while the proliferative index of the tumors is the same as
in Rb+/− animals (Park et al., 1999). Recent genetic evidence
suggests that the absence of p27 prevented Rb−/− cells from
undergoing apoptosis when exposed to normal levels of the
antiproliferative cytokine dopamine, a signal that promotes their
withdrawl from the cell cycle (Carneiro et al., 2003).
The evidence that reduced p27 may contribute to tumor
development by either increasing the proliferation of cells (Pten
prostate model) or decreasing their apoptosis (Rb pituitary
model) might explain why the loss of p27 is a common marker
among many different tumor types. The loss of p27 attenuates
the cell-type specific response to its antimitogenic environment.
The clinical promise and problem with p27
The prognostic and treatment-predictive significance of p27 sta-
tus cannot be understated. Patients with tumors that have low
p27 levels have an inferior prognosis relative to those with high
expression. Decreased overall or disease-free survival has
been seen in numerous human cancers, and suggests that the
clinician should treat these patients aggressively. One approach
considered is gene therapy to restore p27, either directly by
using adenoviral vectors (Katner et al., 2002) or indirectly by
chemically modulating signaling pathways that affect its local-
ization (Shin et al., 2002). Both of these approaches have seen
validation as cytostatic agents in cell lines and xenograft mod-
els, although no human trials have been reported. Enforced
expression of p27 can also have apoptotic consequences as
reported in a transduced oral cancer cell line (Supriatno et al.,
2002) and in T cell acute lymphoblastic leukemia cells (Barata
et al., 2001).
On the other hand, accumulating p27 might have negative
consequences in treatment outcome. High levels of p27 might
inhibit the efficiency of chemotherapies that rely on interfering
with proliferation to trigger a cytostatic or cytotoxic response
through checkpoint activation (reviewed in Chauffert et al.,
1999). In fresh breast cancer specimens analyzed directly for
p27 status and chemotherapeutic sensitivity by histoculture
drug response assay, a marked association between increased
F O C U S
Figure 1. Mouse models recapitulate the role of p27 in human cancers
While p27 null mice are relatively tumor-free, p27 loss enhances the malig-
nancy and frequency of tumor formation in cooperation with different
oncogenic stimuli. p27 null animals were crossed with Rb+/−,
cdk4R24C/R24C, Min/−, Eµ-myc, inhibin−/−, or Pten+/− animals to generate
compound phenotypes. Refer to the text for the specific references to the
studies that generated this figure.
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p27 staining and resistance to doxorubicin was observed (Yang
et al., 2000). Antisense techniques applied in tissue culture
increased chemosensitivity, suggesting promise for such an
approach in human tumors as well (Achenbach et al., 2000; St
Croix et al., 1996).
The duality of p27 as a prognostic marker and the fact that
p27 status can affect cell proliferation should be used to inform
the treatment of a patient. Low p27 status informs the clinician
that he or she is facing an aggressive tumor, and also predicts
that it might respond well to proliferation inhibitory chemothera-
pies, whereas high p27 status informs the clinician that he or
she is facing an indolent tumor which will only poorly respond to
such interventions.Thus, knowing the status of p27 in a particu-
lar tumor should become de rigueur in the clinic when choosing
a particular therapy.
Modulating p27 levels
One important clinical question is how one might modulate the
level of p27 in order to enhance other therapies. In human
tumors, p27 itself or its activity appear to be lost by increased
degradation, cytoplasmic mislocalization, or sequestration. The
abundance of p27 is controlled in a cell-type-specific and
signal-specific manner by the integration of mitogenic and
antimitogenic signaling pathways that affect its translation, sta-
bility, and localization. The Ras/Raf/Mek1 and PI3K/Akt path-
ways, commonly mutated in human cancer, can impact directly
on the abundance and activity of p27, suggesting that targeting
these pathways may indirectly affect the activity of p27 and the
response of cells to other chemotherapeutic treatments.
p27 mRNA levels remain constant
throughout the cell cycle, while its protein
levels are controlled by ubiquitin-mediated
proteolysis at the G0–G1 and G1–S bor-
ders (Nakayama et al., 2001). Not surpris-
ingly, the abundance of p27 in many
tumors correlates with ubiquitin-dependent
proteolytic activity. Recently, a direct inverse correlation
between reduced p27 levels and increased Skp2 levels, a key
component of the p27 ubiquitin-ligase, has been seen in col-
orectal tumors, oral squamous cell carcinomas, and lymphomas
(Chiarle et al., 2002; Gstaiger et al., 2001; Hershko et al., 2001;
Kudo et al., 2001; Latres et al., 2001). In theory, many addition-
al oncogenic insults might directly impinge on p27 stability. For
example, overexpression of PI3K or loss of Pten have been
shown to directly increase Skp2 levels (Mamillapalli et al.,
2001). Numerous studies have demonstrated that overexpres-
sion of Her-2/neu or Ras, and activation of the MAPK pathway
reduces p27 stability (Pruitt and Der, 2001). Likewise, overex-
pression of cyclin E, in breast, stomach or colon carcinomas,
might increase p27 phosphorylation and degradation.
p27 activity also appears to be directly targeted by its mislo-
calization to the cytoplasm in colon, ovarian, breast, and thyroid
tumors (Baldassarre et al., 1999; Ciaprrone et al., 1998;
Hurteau et al., 2001). Cytoplasmic p27 appears to directly cor-
relate with poor long-term survival and tumor grade in Barrett’s
associated adenocarcinoma of the esophagus and breast carci-
noma (Liang et al., 2002; Shin et al., 2002; Singh et al., 1998;
Viglietto et al., 2002). Mislocalization effectively inactivates p27
inhibitory activity, as cytoplasmic p27 is partitioned from its
nuclear cyclin-cdk targets. Cytoplasmic mislocalization of p27
may also be the result of a variety of different oncogenic
assaults. For example, Ras or Her-2/neu overexpression has
been shown to increase p27 levels in the cytoplasm (Liu et al.,
2000; Yang et al., 2000), and oncogenically activated Akt was
shown to directly phosphorylate a Thr residue (T157) in the p27
F O C U S
Figure 2. p27 is targeted by multiple oncogenic
stimuli
The PI3K/Pten/Akt pathway (1) induces Skp2,
resulting in increased ubiquitination and the sub-
sequent degradation of p27, (2) stabilizes cyclin
D1 via inactivation of GSK3-β, resulting in
increased cyclin D1 sequestration of p27, and (3)
directly phosphorylates p27, causing mislocaliza-
tion to the cytoplasm. The Ras/Raf/Mek1 pathway
also (1) increases p27 degradation, (2) induces
cyclin D1 transcription, and (3) causes p27 mislo-
calization to the cytoplasm, perhaps via interac-
tions with Jab1 or KIS phosphorylation. All of these
events result in the inactivation of p27’s inhibitory
activity. Increased cyclin E may cause increased
p27 phosphorylation and subsequent degrada-
tion. While Pten and PI3K have been shown to reg-
ulate Skp2 levels, a direct link between Akt and
Skp2 has not been established, and Akt-indepen-
dent functions of Pten and PI3K have been
described. The MAPK pathway has been shown to
regulate p27 stability via phosphorylation and
degradation, but a direct link between MAPK and
Skp2 has not been demonstrated. A direct corre-
lation between cyclin E, Jab1, KIS, and p27 in
human tumors has not been demonstrated. Loss
of p27 would attenuate antimitogenic signaling,
rendering a cell resistant to certain growth-arrest-
ing stimuli, such as TGF-β.
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NLS motif, causing p27’s cytoplasmic mislocalization (Liang et
al., 2002; Shin et al., 2002; Viglietto et al., 2002).
Sequestration of p27 in the cytoplasm by cyclin D-cdk4/6
complexes is yet another way that p27 might be inactivated in
human tumors. Overexpression of cyclin D3 in thyroid cancers
caused p27 cytoplasmic sequestration by cyclin D3-cdk com-
plexes (Baldassarre et al., 1999). Both the Ras/Raf/Mek1 and
PI3K/Akt pathways may impinge on p27 localization indirectly
by their direct effects on cyclin D levels. MAPK activation upreg-
ulates cyclin D1, and AKT-dependent phosphorylation of GSK3-
β inhibits cyclin D1 degradation (Pruitt and Der, 2001). Both of
these mechanisms would increase the subsequent sequestra-
tion of p27, and prevent association with its targets.
Thus, the inactivation of p27 can be achieved by a number
of different oncogenic stimuli, including amplification of Ras,
cyclin D, loss of Pten, increased RTK activity (HER-2, IGFR,
EGF), increased Akt activity, and increased cyclin E or Skp2
(Figure 2). In fact, p27 may be a powerful prognostic marker
because it is the readout of multiple different pathways involved
in the development of tumors. It also highlights the potential
overlap of these pathways. For example, increased Akt activity
might increase Skp2 and cyclin D1 levels and directly phospho-
rylate p27, all of which may collaborate to promote p27 mislo-
calization and/or degradation. The fact that most of the control
of p27 abundance is posttranscriptional suggests that a pro-
teomic survey, in addition to a genomic survey which is limited
to transcriptional changes, would have prognostic clinical value.
Likewise, attempts to modulate p27 activity or amount, either
directly through its expression or indirectly by targeting signal-
ing pathways that control it, may be a promising approach for
combinatorial chemotherapy.
Future challenges
Clinically, the efficacy of many chemotherapies relies on their
ability to induce DNA damage. p27 induces cell cycle exit, and
thus, its expression can interfere with treatments that work bet-
ter in proliferating cells. In addition, the occasional apoptotic
effect of p27 expression is cell type-specific and dependent on
contextual clues which are only poorly defined at this time.
Thus, we need to be able to predict how cells in a particular
tumor will respond to accumulation of p27. Will this response be
beneficial clinically? Will it interfere with the efficacy of therapies
currently in use, or could it be combined with novel therapeutic
approaches?
One might imagine that therapies could be designed which
capitalize on our knowledge of p27’s role in a specific tumor to
target chemotherapeutic resistant cells. If we could treat initially
resistant cells with an agent that interferes with p27 accumula-
tion or function, we might be able to “push” those cells back into
the cycle, exposing them to the cytotoxic agents when they are
most sensitive; i.e., at a time they are proliferating. Repeated
transitioning in and out of cycle with selective application of
cytotoxic agents might eventually allow all cancer cells to be
eliminated. This type of thinking represents the integration of
what we have learned about p27 in the laboratory and its possi-
ble applications into the clinic.
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